Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate

Virology

Volumn 236, Issue 2, 1997, Pages 364-373

  Quiñones Mateu, Miguel E ^a   Soriano, Vicente ^b   Domingo, Esteban ^a   Menéndez Arias, Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0242692479     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8748     Document Type: Article

References (56)

1. Ahgren C., Backro K., Bell F. W., Cantrell A. S., Clemens M., Colacino J. M., Deeter J. B., Engelhardt J. A., Hogberg M., Jaskunas S. R., Johansson N. G., Jordan C. L., Kasher J. S., Kinnick M. D., Lind P., López C., Morin J. M. Jr., Muesing M. A., Noreen R., Oberg B., Paget C. B., Palkowitz J. A., Parrish C. A., Pranc P., Rippy M. K., Rydergard C., Sahlberg C., Swanson S., Ternansky R. J., Unge T., Vasileff R. T., Vrang L., West S. J., Zhang H., Zhou X.-X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;1329-1335.
2. Blouin J. C., Guzman E. A., Foley B. T. Global variation in the HIV-1 V3 region. Human Retroviruses and AIDS Compendium. 1996;Los Alamos National LaboratoryTheoretical Biology and Biophysics Group, Los Alamos. p. 77-201.
3. Boyer P. L., Currens M. J., McMahon J. B., Boyd M. R., Hughes S. H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67:1993;2412-2420.
4. CPZ. J. Virol. 70:1996;4220-4227.
5. Buckheit R. W. Jr., Kinjerski T. L., Fliakas-Boltz V., Russell J. D., Stup T. L., Pallansch L. A., Brouwer W. G., Dao D. C., Harrison W. A., Schultz R. J., Bader J. P., Yang S. S. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:1995;2718-2727.
6. Byrnes V. W., Sardana V. V., Schleif W. A., Condra J. H., Waterbury J. A., Wolfgang J. A., Long W. J., Schneider C. L., Schlabach A. J., Wolanski B. S., Graham D. J., Gotlib L., Rhodes A., Titus D. L., Roth E., Blahy O. M., Quintero J. C., Staszewski S., Emini E. A. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37:1993;1576-1579.
7. Chao S.-F., Chan V. L., Juranka P., Kaplan A. H., Swanstrom R., Hutchison C. A. III. Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 23:1995;803-810.
8. Charneau P., Borman A. M., Quillent C., Guétard D., Chamaret S., Cohen J., Rémy G., Montagnier L., Clavel F. Isolation and envelope sequence of a highly divergent HIV-1 isolate: Definition of a new HIV-1 group. Virology. 205:1994;247-253.
9. Chattopadhyay D., Evans D. B., Deibel M. R. Jr., Vosters A. F., Eckenrode F. M., Einspahr H. M., Hui J. O., Tomasselli A. G., Zurcher-Neely H. A., Heinrikson R. L., Sharma S. K. Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced byin vitro. J. Biol. Chem. 267:1992;14227-14232.
10. Chou K.-C. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J. Biol. Chem. 268:1993;16938-16948.
11. Delaporte E., Janssens W., Peeters M., Buvé A., Dibanga G., Perret J.-L., Ditsambou V., Mba J.-R., Georges Courbot M.-C., Georges A., Bourgeois A., Samb B., Henzel D., Heyndrickx L., Fransen K., van der Groen G., Larouzé B. Epidemiological and molecular characteristics of HIV infection in Gabon, 1986-1994. AIDS. 10:1996;903-910.
12. De Leys R., Vanderborght B., Vanden Haesevelde M., Heyndrickx L., van Geel A., Wauters C., Bernaerts R., Saman E., Nijs P., Willems B., Taelman H., van der Groen G., Piot P., Tersmette T., Huisman J. G., van Heuverswyn H. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin. J. Virol. 64:1990;1207-1216.
13. Descamps D., Collin G., Loussert-Ajaka I., Saragosti S., Simon F., Brun-Vézinet F. HIV-1 group O sensitivity to antiretroviral drugs. AIDS. 9:1995;977-978.
14. Di Marzo Veronese F., Copeland T. D., DeVico A. L., Rahman R., Oroszlan S., Gallo R. C., Sarangadharan M. G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science. 231:1986;1289-1291.
15. Ding J., Das K., Tantillo C., Zhang W., Clark A. D. Jr., Jessen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Pauwels R., Moereels H., Koymans L., Janssen P. A. J., Smith R. H. Jr., Kroeger Koepke M., Michejda C. J., Hughes S. H., Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure. 3:1995;365-379.
16. E. Domingo, L. Menéndez-Arias, M. E. Quiñones-Mateu, A. Holguín, M. Gutiérrez-Rivas, M. A. Martínez, J. Quer, I. S. Novella, J. J. Holland, 1997, Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants, Progress in Drug Research, 99, 128, Birkhäuser Verlag, Basel, Switzerland.
17. Erickson J. W., Burt S. K. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36:1996;545-571.
18. Fan N., Rank K. B., Poppe S. M., Tarpley W. G., Sharma S. K. Characterization of the p68/p58 heterodimer of human immunodeficiency virus type 2 reverse transcriptase. Biochemistry. 35:1996;1911-1917.
19. Felsenstein J. PHYLIP-Phylogeny inference package. Cladistics. 5:1989;164-166.
20. Gould K., Britvan L., Dryjanski J. HIV-1 group O infection in the USA. Lancet. 348:1996;680-681.
21. Gu Z., Fletcher R. S., Arts E. J., Wainberg M. A., Parniak M. A. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitorsin vitro. J. Biol. Chem. 269:1994;28118-28122.
22. Gürtler L. G., Hauser P. H., Eberle J., von Brunn A., Knapp S., Zekeng L., Tsague J. M., Kaptue L. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68:1994;1581-1585.
23. Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 326:1987;662-669.
24. Hampl H., Sawitzky D., Stöffler-Meilicke M., Groh A., Schmitt M., Eberle J., Gurtler L. First case of HIV-1 subtype O infection in Germany. Infection. 23:1995;369-370.
25. Heyndrickx L., Alary M., Janssens W., Davo N., van der Groen G. HIV-1 group O and group M dual infection in Bénin. Lancet. 347:1996;902-903.
26. Hirsch V. M., Dapolito G. A., Goldstein S., McClure H., Emau P., Fultz P. N., Isahakia M., Lenroot R., Myers G., Johnson P. R. A distinct African lentivirus from Sykes' monkeys. J. Virol. 67:1993;1517-1528.
27. Hizi A., McGill C., Hughes S. H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase inEscherichia coli. Proc. Natl. Acad. Sci. USA. 85:1988;1218-1222.
28. Hizi A., Tal R., Shaharabany M., Loya S. Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem. 266:1991;6230-6239.
29. Jacobo-Molina A., Arnold E. HIV reverse transcriptase structure-function relationships. Biochemistry. 30:1991;6351-6361.
30. Kimura M. A simple model for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16:1980;111-120.
31. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steitz T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
32. Korber B., Loussert-Ajaka I., Blouin J., Saragosti S. A comparison of HIV-1 group M and group O functional and immunogenic domains in the Gag p24 protein and the C2V3 region of the envelope protein. Human Retroviruses and AIDS Compendium. 1996;Los Alamos National LaboratoryTheoretical Biology and Biophysics Group, Los Alamos. p. 63-79.
33. Le Grice S. F. J., Naas T., Wohlgensinger B., Schatz O. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J. 10:1991;3905-3911.
34. Loussert-Ajaka I., Ly T. D., Chaix M. L., Ingrand D., Saragosti S., Couroucé A. M., Brun-Vézinet F., Simon F. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet. 343:1994;1393-1394.
35. Loussert-Ajaka I., Chaix M.-L., Korber B., Letourneur F., Gomas E., Allen E., Ly T.-D., Brun-Vézinet F., Simon F., Saragosti S. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J. Virol. 69:1995;5640-5649.
36. Loya S., Bakhanashvili M., Tal R., Hughes S. H., Boyer P. L., Hizi A. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (Tyrosine 181 → Isoleucine and Tyrosine 188 → Leucine), resistant to nonnucleoside inhibitors. AIDS Res. Human Retrovir. 10:1994;939-946.
37. Martin J. L., Wilson J. E., Haynes R. L., Furman P. A. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Natl. Acad. Sci. USA. 90:1993;6135-6139.
38. Martín-Hernández A. M., Domingo E., Menéndez-Arias L. Human immunodeficiency virus type 1 reverse transcriptase: Role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. EMBO J. 15:1996;4434-4442.
39. Martín-Hernández A. M., Gutiérrez-Rivas M., Domingo E., Menéndez-Arias L. Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. Nucleic Acids Res. 25:1997;1383-1389.
40. Mas A., Quiñones-Mateu M. E., Soriano V., Domingo E. env. AIDS Res. Human Retrovir. 12:1996;1647-1649.
41. Mauclère P., Loussert-Ajaka I., Damond F., Fagot P., Souquières S., Monny Lobe M., Mbopi Keou F.-X., Barré-Sinoussi F., Saragosti S., Brun-Vézinet F., Simon F. Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS. 11:1997;445-453.
42. Mellors J. W., Schinazi R. F., Larder B. A. Mutations in retroviral genes associated with drug resistance. Human Retroviruses and AIDS Compendium. 1996;Los Alamos National LaboratoryTheoretical Biology and Biophysics Group, Los Alamos. p. 206-241.
43. Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C.-K., Eckner K., Hattox S., Adams J., Rosehthal A. S., Faanes R., Eckner R. J., Koup R. A., Sullivan J. L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250:1990;1411-1413.
44. Mulanga Kabeya C., Esu-Williams E., Eni E., Peeters M., Saman E., Delaporte E. Evidence for HIV-1 group O infection in Nigeria. Lancet. 346:1995;308.
45. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreese K., Woestenborghs R., Vandamme A.-M., Janssen C. G. M., Anne J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M. A. C., De Clercq E., Janssen P. A. J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA. 90:1993;1711-1715.
46. Peeters M., Gueye A., Mboup S., Bibollet-Ruche F., Ekaza E., Mulanga C., Ouedrago R., Gandji R., Mpele P., Dibanga G., Koumare B., Saidou M., Esu-Williams E., Lombart J.-P., Badombena W., Luo N., Vanden Haesevelde M., Delaporte E. Geographical distribution of HIV-1 group O viruses in Africa. AIDS. 11:1997;493-498.
47. Poorman R. A., Tomasselli A. G., Heinrikson R. L., Kézdy F. J. A cumulative specificity model for proteases from human immunodeficiency virus type 1 and 2, inferred from statistical analysis of an extended substrate data base. J. Biol. Chem. 266:1991;14554-14561.
48. Quiñones-Mateu M. E., Dopazo J., Esté J. A., Rota T. R., Domingo E. Molecular characterization of human immunodeficiency virus type 1 isolates from Venezuela. AIDS Res. Human Retrovir. 11:1995;605-616.
49. Quiñones-Mateu M. E., Holguín A., Dopazo J., Nájera I., Domingo E. Point mutant frequencies in thepolenv. AIDS Res. Human Retrovir. 12:1996;1117-1128.
50. Reardon J. E., Furfine E. S., Cheng N. Human immunodeficiency virus reverse transcriptase. Effect of primer length on template-primer binding. J. Biol. Chem. 266:1991;14128-14134.
51. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C. K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
52. Schable C., Zekeng L., Pau C.-P., Hu D., Kaptue L., Gurtler L., Dondero T., Tsague J.-M., Schochetman G., Jaffe H., George J. R. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet. 344:1994;1333-1334.
53. Songok E. M., Libondo D. K., Rotich M. C., Oogo S. A., Tukei P. M. Surveillance for HIV-1 subtypes O and M in Kenya. Lancet. 347:1996;1700.
54. Soriano V., Gutiérrez M., García-Lerma G., Aguilera O., Mas A., Bravo R., Pérez-Labad M., Baquero M., González-Lahoz J. First case of HIV-1 group O infection in Spain. Vox Sang. 71:1996;66.
55. Vanden Haesevelde M., Decourt J.-L., De Leys R. J., Vanderborght B., van der Groen G., van Heuverswijn H., Saman E. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J. Virol. 68:1994;1586-1596.
56. Zhang H., Vrang L., Bäckbro K., Lind P., Sahlberg C., Unge T., Öberg B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antivir. Res. 28:1995;331-342.